The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.
Sofi-cel, an allogeneic, off-the-shelf, CD7-targeted CAR-T cell therapy, has previously received regenerative medicine advanced therapy, fast track, orphan drug, and rare pediatric disease
The United States Food and Drug Administration cleared the Investigational New Drug application for KLN-1010, an in vivo BCMA-targeted CAR-T therapy, for patients
The Malaysian National Pharmaceutical Regulatory Agency approved selinexor (XPOVIO) for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after at
n this video interview with SOHO Insider, Guillermo García-Manero, MD, professor and chief of the Section of Myelodysplastic Syndromes and ad interim chair
Registration is now officially open for the Fourteenth Annual Meeting of the Society of Hematologic Oncology. The event is scheduled for September 9
In this video, the group discusses adding novel agents to frontline chemotherapy in large B-cell lymphoma, including polatuzumab vedotin with R-CHOP and bispecific
In this video interview with SOHO Insider, Pan-Yu Chen, PhD, associate director of Translational Medicine at Opna Bio, presents her ASH abstract on
In this video, the panel discusses follicular lymphoma treatment options in 2025.
"We have so much potential, so many lives dedicated to treatment and prevention of blood cancers, terabytes of data on immune function and
In this video interview with SOHO Insider, Adam Mead, MD, professor of hematology at the University of Oxford and lead author on the
